A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation

Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients With Early-stage Parkinson's Disease Carrying a GBA Mutation or Other Pre-specified Variant.

Recruitment Information:

Seeking volunteers with following diagnosis: PD Study Type: Interventional
Eligible Ages: 18 - 80 Status: Recruiting
Time Since Diagnosis: Any may be eligible Study Focus: Cause of PD, Genetics

Study Purpose:

Millions of people live with Parkinson’s disease, a condition that causes damage to a part of the brain in ways that make daily life challenging for patients.

While the exact causes are unknown, an estimated 5 – 10% of cases are linked to a genetic mutation (a GBA mutation) that puts them at risk of having an earlier appearance of PD symptoms and faster loss of mental and motor skills than those PD patients with no GBA mutation. However, a study of PD patients with this mutation and treatment has not been done yet. This research study is the first study to identify patients with this mutation (using a saliva sample) and evaluate how they respond to an investigational treatment that targets the pathway of the mutation.

The drug being tested targets the pathway where this mutation is located and ‘normalizes’ the cell activity. The drug is called SAR402671, and it is an experimental medication (one that has not been approved yet) being developed by the Sponsor of the clinical trial. There will be 2 parts to the study. Part 1 will first evaluate how tolerable the drug is in a small number of patients. Part 2 will then evaluate how effective the drug is in improving symptoms of GBA-mutation positive PD patients. If selected to be in this study, the total study duration in Part 1 will be up to 9 months.

Part 2 will be approximately 42 months that will include 6.5 weeks of screening period, 12 months of treatment period, 26 months of follow-up period, and 6 weeks of post-treatment observation period.

This study will also help further researchers’ understanding of GBA mutations, which may be helpful to other patients. If interested in learning more visit: http://mediaroom.sanofi.com/persistence-and-accidental-inspiration-propel-parkinsons-research/

Find a Site Location and Contact the Trial Team

More Details

The total study duration per subject in Part 2 will be approximately 168 weeks that will consist of 6.5 weeks of screening period, 52 weeks of treatment period, 104 weeks of follow-up period, and 6 weeks of post-treatment observation period. Part 1 maximal duration will be up to 48 weeks outside Japan, and up to 64 weeks in Japan.

Phase: Phase 2 Lead Sponsor: Genzyme, a Sanofi Company
Trial ID: 004756 Sponsor Type: Industry
Primary Country: Austria Additional Collaborators or Sponsors:
Estimated Enrollment: 243 Study Start Date: December 2016
Estimated Study Completion Date: April 2022 Source: ClinicalTrials.gov
Study Website:

More Inclusion & Exclusion Criteria

Share This Trial

Fox Trial Finder strives to make all trial postings as accurate and complete as possible. If you believe any of the information on this page is not accurate, click here to contact us. Thank you for your support.

Choose your location

Please select a Trial Location.


You have favorited this trial!

This trial will be listed in the "Favorites" category of your dashboard.


You are not interested.

This trial will be listed in the "Not Interested" category on your dashboard. You can click "Interested" if you change your mind.

Message to Trial Coordinator

Your message was sent.

Your message was sent to the trial team at the location you selected. Check your dashboard for a response.

Login to My Trial Finder

Please enter your email address and password to access your My Fox Trial Finder dashboard.

*indicates required field.

Contact Fox Trial Finder

What best describes you?

*indicates required field.